For U.S. Residents Only

NOW
APPROVED

DSUVIA (sufentanil) sublingual
tablet 30 mcg

About AcelRx

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.

Zalviso: In Phase III

Zalviso™Zalviso™

Approved in Europe, Zalviso delivers a 15 mcg sublingual dose of sufentanil via a novel preprogrammed device—providing an alternative to IV patient-controlled analgesia in the hospital.

proprietary sublingual technology

DSUVIA™ and Zalviso® were both developed using this proprietary sublingual technology.

Learn More